Fluphenazine pharmacokinetics and therapeutic response

Abstract

We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCl over a 2-week period. Both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (±SD) was 16.4±13.3 h. We found that concomitant use of benztropin mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.